MBP and nervous system disorder: However, its combination with other biomarkers, such as glial fibrillary acid protein GFAP, Myelin basic protein (MBP), and interleukins, could provide disease-specific signatures to discriminate between neurological disorders in the future—a currently unmet need in the real-world clinical setting.